Evidence map›Paper›PMID 34765540›Full record

ArticleFrontiers in oncology2021

LncRNA FOXP4-AS1 Promotes Progression of Ewing Sarcoma and Is Associated With Immune Infiltrates.

Jiachao Xiong, Liang Wu, Lu Huang, Chunyang Wu, Zhiming Liu, Wenqiang Deng, Shengbiao Ma, Zhenhai Zhou, Honggui Yu, Kai Cao

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jiachao XiongThe Orthopedics Hospital, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Liang WuThe Orthopedics Hospital, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Lu HuangChild Health Department of the Maternal and Children Health Hospital of Jiangxi Province, Nanchang, China.
Chunyang WuThe Orthopedics Hospital, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Zhiming LiuThe Orthopedics Hospital, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Wenqiang DengThe Orthopedics Hospital, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Shengbiao MaThe Orthopedics Hospital, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Zhenhai ZhouThe Orthopedics Hospital, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Honggui YuThe Orthopedics Hospital, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Kai CaoThe Orthopedics Hospital, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Nanchang University · CNFirst Affiliated Hospital of Nanchang University · CNJiangxi Maternal and Child Health Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ewing sarcoma (ES) is a highly malignant primary bone tumor with poor prognosis. Studies have shown that abnormal expression of lncRNA influences the prognosis of tumor patients. Herein, we established that FOXP4-AS1 was up-regulated in ES and this correlated with poor prognosis. Further analysis illustrated that FOXP4-AS1 down-regulation repression growth, migration, along with invasion of ES. On the contrary, up-regulation of FOXP4-AS1 promoted the growth, migration, as well as invasion of ES. To explore the mechanism of FOXP4-AS1, Spearman correlation analysis was carried out to determine genes that were remarkably linked to FOXP4-AS1 expression. The potential functions and pathways involving FOXP4-AS1 were identified by GO analysis, Hallmark gene set enrichment analysis, GSEA, and GSVA. The subcellular fractionation results illustrated that FOXP4-AS1 was primarily located in the cytoplasm of ES cells. Then a ceRNA network of FOXP4-AS1 was constructed. Analysis of the ceRNA network and GSEA yielded two candidate mRNAs for FOXP4-AS1. Results of the combined survival analysis led us to speculate that FOXP4-AS1 may affect the expression of TMPO by sponging miR-298, thereby regulating the malignant phenotype of ES. Finally, we found that FOXP4-AS1 may modulates the tumor immune microenvironment in an extracellular vesicle-mediated manner. In summary, FOXP4-AS1 correlates with poor prognosis of ES. It promotes the growth, migration, as well as invasion of ES cells and may modulate the tumor immune microenvironment.

Indexed as

ceRNAEwing sarcomaextracellular vesiclesFOXP4-AS1tumor immune microenvironment

Identifiers

PMID34765540
PMCPMC8577041
OpenAlexW3209467174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.